Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain LOXO message board posts where the ticker symbol LOXO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest LOXO SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-008386 Size: 14 KB
2018-02-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-008377 Size: 31 KB
2018-02-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-18-008379 Size: 23 KB
2018-02-14
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000080255-18-002576 (34 Act)  Size: 6 KB
2018-02-14 005-88267
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001140361-18-007892 (34 Act)  Size: 11 KB
2018-02-14 005-88267
18610171
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000902664-18-000981 (34 Act)  Size: 105 KB
2018-02-13 005-88267
18603788
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-001367 (34 Act)  Size: 9 KB
2018-02-13 005-88267
18599922
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-18-003471 (34 Act)  Size: 45 KB
2018-02-09 005-88267
18588433
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001040188-18-000046 (34 Act)  Size: 43 KB
2018-02-08 005-88267
18585663
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000902219-18-000336 (34 Act)  Size: 37 KB
2018-02-08 005-88267
18584210
More LOXO SEC Filings


Related news from
Fri, 02 Feb 2018
13:06:58 +0000
See what the IHS Markit Score report has to say about Loxo Oncology Inc.
Loxo Oncology Inc NASDAQ NMS:LOXO
Wed, 31 Jan 2018
15:34:26 +0000
Array BioPharma’s Financial Performance
What Led to Array BioPharma's Stellar Returns in Past 6 Months
Wed, 31 Jan 2018
14:03:25 +0000
Array BioPharma’s ARRY-382 and ARRY-797
What Led to Array BioPharma's Stellar Returns in Past 6 Months
Thu, 25 Jan 2018
14:02:22 +0000
Taking Stock of Arrowhead Pharmaceuticals’ Financial Performance
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
Thu, 25 Jan 2018
12:32:58 +0000
What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
Wed, 24 Jan 2018
18:30:02 +0000
Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
Arrowhead Pharmaceuticals: A Promising Drug Pipeline
Wed, 24 Jan 2018
17:00:02 +0000
Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform
Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle. In November 2016, the company announced that it would be discontinuing all clinical programs that utilized EX1 and refocusing its efforts on therapies that exclusively utilize Arrowhead’s targeted RNAi molecule (or TRIM) platform. Therapies based on the TRiM platform have demonstrated high levels of pharmacologic activity in numerous animal models that span several therapeutic areas.
Wed, 24 Jan 2018
15:25:38 +0000
Analysts’ Recommendations for Arrowhead and Its Peers
Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.
Wed, 10 Jan 2018
12:37:55 +0000
Inside Ignyta’s Financial Performance
Ignyta and Its Drug Candidates for 2018
Tue, 09 Jan 2018
19:15:03 +0000
A Close Look at Ignyta’s Licensing Agreement
The agreement granted Ignyta exclusive global rights to develop and commercialize entrectinib. Under the license, Ignyta’s development rights are exclusive for entrectinib for the term of the agreement. The license also grants exclusive rights to Ignyta for a term of five years with respect to any product candidate that NMS might develop that has activity against the target proteins of entrectinib.
Tue, 09 Jan 2018
17:41:28 +0000
Analyst Recommendations for Ignyta and Its Peers in January 2018
Delaware-based Ignyta (RXDX) is focused on precision medicine in oncology. It endeavors to eradicate residual disease or the source of a reoccurrence of cancer in targeted patient populations. Ignyta is pursuing an integrated therapeutic and diagnostic strategy to treat cancer patients.
Fri, 22 Dec 2017
21:13:13 +0000
Christmas Comes Early For These 5 Biotechnology Stocks
Biotech stocks rallied on Friday amid a strategic acquisition by Swiss drug maker Roche and regulatory approvals.
Fri, 22 Dec 2017
19:00:00 +0000
Roche Jumps Into Mergers and Acquisitions With $1.7 Billion Deal
The pharmaceutical giant is making a big bet on drugs that treat cancer in an entirely novel way.
Wed, 20 Dec 2017
11:46:00 +0000
Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers
WHIPPANY, N.J., Dec. 20, 2017 /PRNewswire/ -- Bayer today announced that its collaboration partner Loxo Oncology, Inc., (LOXO) has initiated the submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib.  The NDA is being submitted for the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments.
Wed, 20 Dec 2017
11:45:00 +0000
Loxo Oncology Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancers
STAMFORD, Conn., Dec. 20, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...
Mon, 04 Dec 2017
11:48:00 +0000
Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers
WHIPPANY, N.J., Dec. 4, 2017 /PRNewswire/ -- Bayer and Loxo Oncology, Inc., (LOXO), today announced updated clinical data from the larotrectinib (LOXO-101) pediatric Phase I SCOUT trial (NCT02637687). Bayer and Loxo Oncology are jointly developing larotrectinib, an investigational compound being studied for the treatment of patients with cancers harboring tropomyosin receptor kinase (TRK) gene fusions, which are genetic alterations present across a wide range of tumors resulting in uncontrolled TRK signaling and tumor growth.
Mon, 04 Dec 2017
11:45:00 +0000
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
–94 Percent of All Pediatric Patients Remain on Larotrectinib or Received Surgery with Curative Intent–. –Larotrectinib Demonstrates Central Nervous System Activity with First-Ever TRK Fusion Glioblastoma ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I absolutely LOVE ValueForum, and consider this site the most important tool I have for investing and/or trading because of the incredible information at just one site. I have learned so much from reading messages posted here that I recommend to the new comer to select an area of investing that is of interest and then read those posts starting with most current. I am sure you will gain information and learn techniques that can be applied to other areas/sectors of investing. This is an 'Invaluable' forum." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards